netFormulary Oxfordshire Clinical Commissioning Group NHS
Formulary  
 Search
 Formulary Chapter 1: Gastro-intestinal system - Full Chapter
01.05.03  Expand sub section  Drugs affecting the immune response
Cytotoxic Drug Azathioprine
(Gastroenterology)
View adult BNF View SPC online View childrens BNF
Formulary
Amber Shared Care Protocol

For inflammatory bowel disease in line with Shared Care Protocol.

APCO May 2011.

 
   
Ciclosporin
(Gastroenterology)
View adult BNF View SPC online View childrens BNF
Formulary
Amber Shared Care Protocol

*Ciclosporin must be prescribed by BRAND NAME.*

For induction and remission of ulcerative colitis (unlicensed) in line with Shared Care Protocol.

APCO May 2015.

 
Link  UKMI Q&A: Brand name prescribing in primary care
   
Cytotoxic Drug Mercaptopurine
(Gastroenterology)
View adult BNF View SPC online View childrens BNF
Formulary
Amber Shared Care Protocol

For the treatment of inflammatory bowel disease in line with Shared Care Protocol.

APCO November 2015.

 
   
Cytotoxic Drug Methotrexate 2.5mg tablets
(Gastroenterology)
View adult BNF View SPC online View childrens BNF
Formulary
Amber Shared Care Protocol

Only 2.5mg tablets should be prescribed and dispensed to avoid potentially fatal errors.

For use in adults and paediatrics line with Shared Care Protocol for:

  • Dermatology
  • Neurology
  • Gastroenterology
  • Respiratory

Rheumatology

For rheumatology please prescribe in line with Shared Care Protocol here. 

APCO September 2019

Opthalmology

For opthalmology (ocular inflammation) please prescribe in line with Shared Care Protocol here. 

APCO May 2019.

 
   
Cytotoxic Drug Methotrexate injection (Metoject®)
(Gastroenterology)
View adult BNF View SPC online View childrens BNF
Formulary
Amber Shared Care Protocol

*Metoject® injection is the first choice brand of injection which should be used in Oxfordshire*

For use in adults and paediatrics line with Shared Care Protocol for:

  • Dermatology
  • Neurology
  • Gastroenterology
  • Respiratory

Rheumatology

For rheumatology please prescribe in line with Shared Care Protocol here. 

APCO September 2019

Opthalmology

For opthalmology (ocular inflammation) please prescribe in line with Shared Care Protocol here. 

APCO May 2019.

 
   
Vedolizumab (Entyvio®)
(Gastroenterology)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
BlueTeq

For the treatment of:

    • Moderately to severely active ulcerative colitis as per NICE TA342 (APCO July 2015). Also see Clinical Commissioning Policy 263 (ulcerative colitis in adults).
    • Moderately to severely active Crohn's disease after prior therapy as per NICE TA352 (APCO January 2017).

 

 
Link  NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Link  NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
   
01.05.03  Expand sub section  Cytokine inhibitors
Adalimumab (Humira®)
(Gastroenterology)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
BlueTeq

For the treatment of:

 

 
Link  NICE TA187: Crohn’s disease - infliximab and adalimumab
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
   
Golimumab (Simponi®)
(Gastroenterology)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
BlueTeq

For treating moderately to severely active ulcerative colitis after the failure of conventional therapy as per NICE TA329. Also see Clinical Commissioning Policy 263 (ulcerative colitis in adults).

APCO March 2013.

 
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
   
Infliximab
(Gastroenterology)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
BlueTeq

For the treatment of:

 
Link  NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Link  NICE TA187: Crohns disease - infliximab & adalimumab
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Link  SPS: Biosimilars of infliximab guidance
   
Ustekinumab (Stelara®)
(Gastroenterology)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
BlueTeq

For treating moderately to severely active Crohn’s disease after previous treatment as per NICE TA456.

APCO September 2017.

 
Link  NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease
   
 ....
 Non Formulary Items
Darvadstrocel  (Alofisel®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black

Not recommended for treating complex perianal fistulas in Crohn’s disease as per NICE TA556. 

APCO March 2019.

Link  NICE TA556: Darvadstrocel for treating complex perianal fistulas in Crohn’s disease
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Red: Medicines which should only be prescribed in secondary care by a specialist.  

Amber Continuation

Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.   

Amber Shared Care Protocol

Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).   

Green

Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.   

Brown

Brown: Medicines which should only be prescribed in restricted circumstances.  

Black

Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.  

OCCG Green

not used  

netFormulary